{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:37:09Z","timestamp":1781055429363,"version":"3.54.1"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.metabol.2021.154889","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T10:51:09Z","timestamp":1631703069000},"page":"154889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Future directions in insulin therapy"],"prefix":"10.1016","volume":"124","author":[{"given":"Philip","family":"Home","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2021.154889_bb0005","series-title":"The discovery of insulin","author":"Bliss","year":"2000"},{"key":"10.1016\/j.metabol.2021.154889_bb0010","doi-asserted-by":"crossref","first-page":"108816","DOI":"10.1016\/j.diabres.2021.108816","article-title":"The evolution of insulin therapy","volume":"175","author":"Home","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2021.154889_bb0015","doi-asserted-by":"crossref","first-page":"108819","DOI":"10.1016\/j.diabres.2021.108819","article-title":"The history of the Nobel prize for the discovery of insulin","volume":"175","author":"Ryd\u00e9n","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2021.154889_bb0020","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.2337\/dc15-2229","article-title":"Trends in insulin use and diabetes control in the U.S: 1988-1994 and 1999-2012","volume":"39","author":"Selvin","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154889_bb0025","doi-asserted-by":"crossref","DOI":"10.2337\/cd20-0098","article-title":"Type 1 diabetes management with technology: patterns of utilization and effects on glucose control using real-world evidence","author":"Sun","year":"2021","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2337\/diab.45.2.223","article-title":"A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm","volume":"45","author":"Matschinsky","year":"1996","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s125-002-8240-x","article-title":"The in vivo regulation of pulsatile insulin secretion","volume":"45","author":"P\u00f8rksen","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dom.12117","article-title":"Hepatoselectivity and the evolution of insulin","volume":"16","author":"Herring","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0045","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00253868","article-title":"A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique","volume":"22","author":"Home","year":"1982","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0050","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/BF01788901","article-title":"Basal and 24-h C-peptide and insulin secretion rate in normal man","volume":"30","author":"Kruszynska","year":"1987","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0055","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0060","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s40262-014-0165-y","article-title":"A review of the pharmacological properties of insulin degludec and their clinical relevance","volume":"53","author":"Haahr","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2021.154889_bb0065","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/pedi.12358","article-title":"Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec\/insulin aspart in children, adolescents, and adults with type 1 diabetes","volume":"17","author":"Biester","year":"2016","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0070","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2337\/dc09-0595","article-title":"Changes in basal insulin infusion rates with subcutaneous insulin infusion: time until a change in metabolic effect is induced in patients with type 1 diabetes","volume":"32","author":"Heinemann","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl. 2","key":"10.1016\/j.metabol.2021.154889_bb0075","first-page":"S3","article-title":"Continuous glucose monitoring: a review of successes, challenges, and opportunities","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Tech Ther"},{"key":"10.1016\/j.metabol.2021.154889_bb0080","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00125-021-05391-w","article-title":"New closed-loop insulin systems","volume":"64","author":"Boughton","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/dom.13963","article-title":"The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications","volume":"22","author":"Owens","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(21)00170-4","article-title":"Restoring normal islet mass and function in type 1 diabetes through regenerative medicine and tissue engineering","author":"Krentz","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154889_bb0095","series-title":"Modern tools for genetic engineering","article-title":"Insulin gene therapy for type 1 diabetes mellitus: unique challenges require innovative solutions","author":"Handorf","year":"2016"},{"key":"10.1016\/j.metabol.2021.154889_bb0100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s00125-021-05422-6","article-title":"\u2018Smart\u2019 insulin-delivery technologies and intrinsic glucose-responsive insulin analogues","volume":"64","author":"Jarosinski","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0105","doi-asserted-by":"crossref","first-page":"101107","DOI":"10.1016\/j.molmet.2020.101107","article-title":"Glucose-sensitive insulin","volume":"46","author":"Hoeg-Jensen","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0110","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2337\/db17-0577","article-title":"Engineering glucose responsiveness into insulin","volume":"67","author":"Kaarsholm","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0115","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/cpt.1215","article-title":"Clinical evaluation of MK-2640: an insulin analog with glucose-responsive properties","volume":"105","author":"Krug","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.metabol.2021.154889_bb0120","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.2337\/dbi20-0011","article-title":"Smarter modeling to enable a smarter insulin","volume":"69","author":"Taylor","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0125","article-title":"Insertion of a synthetic switch into insulin provides metabolite-dependent regulation of hormone\u2013receptor activation","volume":"118","author":"Chena","year":"2021","journal-title":"PNAS"},{"key":"10.1016\/j.metabol.2021.154889_bb0130","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.cmet.2021.03.021","article-title":"Human pluripotent stem cell-derived insulin-producing cells: a regenerative medicine perspective","volume":"33","author":"Migliorini","year":"2021","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0135","first-page":"80","article-title":"Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of type I diabetes","volume":"97","author":"Sutherland","year":"1984","journal-title":"Trans Assoc Am Physicians"},{"key":"10.1016\/j.metabol.2021.154889_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF00273866","article-title":"Comparison of portal and peripheral insulin delivery on carbohydrate metabolism in streptozotocin-diabetic rats","volume":"28","author":"Kruszynska","year":"1985","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2021.154889_bb0145","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2337\/diab.34.6.611","article-title":"Comparison of portal and peripheral insulin delivery on lipid metabolism in streptozotocin-diabetic rats","volume":"34","author":"Kruszynska","year":"1985","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omtm.2017.03.008","article-title":"Long-term efficacy and safety of insulin and glucokinase gene therapy for diabetes: 8-year follow-up in dogs","volume":"6","author":"Ja\u00e9n","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.metabol.2021.154889_bb0155","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/bmj.1.6107.204","article-title":"Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia","volume":"1","author":"Pickup","year":"1978","journal-title":"Br Med J"},{"key":"10.1016\/j.metabol.2021.154889_bb0160","doi-asserted-by":"crossref","first-page":"877","DOI":"10.2337\/diacare.15.7.877","article-title":"Clinical trial of programmable implantable insulin pump for type i diabetes","volume":"15","author":"Selam","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154889_bb0165","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.2147\/IJN.S283416","article-title":"Advances in subcutaneous delivery systems of biomacromolecular agents for diabetes treatment","volume":"16","author":"Li","year":"2021","journal-title":"Int J Nanomed"},{"key":"10.1016\/j.metabol.2021.154889_bb0170","doi-asserted-by":"crossref","first-page":"73","DOI":"10.18433\/jpps29610","article-title":"Microneedles as enhancer of drug absorption through the skin and applications in medicine and cosmetology","volume":"21","author":"Serrano-Casta\u00f1eda","year":"2018","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.metabol.2021.154889_bb0175","doi-asserted-by":"crossref","first-page":"13755","DOI":"10.1073\/pnas.2331316100","article-title":"Microfabricated needles for transdermal delivery of macromolecules and nanoparticles: fabrication methods and transport studies","volume":"24","author":"McAllister","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.metabol.2021.154889_bb0180","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41378-020-00224-z","article-title":"Smartphone-powered iontophoresis-microneedle array patch for controlled transdermal delivery","volume":"6","author":"Yang","year":"2020","journal-title":"Microsyst Nanoeng"},{"key":"10.1016\/j.metabol.2021.154889_bb0185","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1152\/ajplegacy.1923.67.1.65","article-title":"The absorption of insulin from the intestine, vaginal, and scrotal sac","volume":"67","author":"Fisher","year":"1923","journal-title":"Am J Physiol"},{"key":"10.1016\/j.metabol.2021.154889_bb0190","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1046\/j.1464-5491.2003.01076.x","article-title":"Alternative routes of insulin delivery","volume":"20","author":"Owens","year":"2003","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2021.154889_bb0195","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/ijerph17165795","article-title":"A review: the prospect of inhaled insulin therapy via vibrating mesh technology to treat diabetes","volume":"17","author":"Cunningham","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.metabol.2021.154889_bb0200","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1464-5491.1991.tb01611.x","article-title":"Meal-time intranasal insulin delivery in type 2 diabetes","volume":"8","author":"Bruce","year":"1991","journal-title":"Diabet Med"},{"key":"10.1016\/j.metabol.2021.154889_bb0205","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2337\/diacare.10.5.573","article-title":"Long-term use of intranasal insulin in insulin-dependant diabetic patients","volume":"10","author":"Frauman","year":"1987","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154889_bb0210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1177\/193229680900300323","article-title":"Oral insulin and buccal insulin: a critical reappraisal","volume":"3","author":"Heinemann","year":"2009","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.metabol.2021.154889_bb0215","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0304-4165(82)90267-7","article-title":"Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs","volume":"716","author":"Patel","year":"1982","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.metabol.2021.154889_bb0220","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-021-01025-x","article-title":"Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials","author":"Overgaard","year":"2021","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.metabol.2021.154889_bb0225","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1038\/s41467-020-17487-9","article-title":"Molecular engineering of safe and efficacious oral basal insulin","volume":"11","author":"Hub\u00e1lek","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2021.154889_bb0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S2213-8587(18)30372-3","article-title":"Efficacy and safety of oral basal insulin versus subcutaneous insulin glargine in type 2 diabetes: a randomised, double-blind, phase 2 trial","volume":"7","author":"Halberg","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.metabol.2021.154889_bb0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1463-1326.2010.01213.x","article-title":"A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects","volume":"12","author":"Khedkar","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0240","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/cpdd.730","article-title":"Pharmacokinetics and pharmacodynamics of insulin tregopil in relation to premeal dosing time, between meal interval, and meal composition in patients with type 2 diabetes mellitus","volume":"9","author":"Khedkar","year":"2020","journal-title":"Clin Pharm Drug Dev"},{"key":"10.1016\/j.metabol.2021.154889_bb0245","author":"Oramed"},{"issue":"suppl 1","key":"10.1016\/j.metabol.2021.154889_bb0250","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.2337\/db20-1004-P","article-title":"Oral insulin (ORMD-0801) effects on glucose parameters in uncontrolled T2DM on OADs. (Meeting abstract.)","volume":"69","author":"Eldor","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0255","series-title":"EASD Virtual meeting","article-title":"Evening oral insulin (ORMD-0801): glycemic effects in uncontrolled T2DM patients","volume":"60","author":"Eldor","year":"2020"},{"key":"10.1016\/j.metabol.2021.154889_bb0260","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.2337\/dc19-2316","article-title":"Impact of a weekly glucagon-like peptide 1 receptor agonist, albiglutide, on glycemic control and on reducing prandial insulin use in type 2 diabetes inadequately controlled on multiple insulin therapy: a randomized trial","volume":"43","author":"Rosenstock","year":"2020","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.metabol.2021.154889_bb0265","article-title":"Basal insulin Fc (BIF), a novel insulin suited for once weekly dosing for the treatment of patients with diabetes mellitus. (Abstract.)","volume":"5","author":"Heise","year":"2021","journal-title":"J Endo Soc"},{"key":"10.1016\/j.metabol.2021.154889_bb0270","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1021\/acs.jmedchem.1c00257","article-title":"Molecular engineering of insulin icodec, the first acylated insulin analog for once-weekly administration in humans","volume":"64","author":"Kjeldsen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2021.154889_bb0275","series-title":"EASD Virtual Meeting","article-title":"Insulin icodec, an insulin analog suited for once-weekly dosing in type 2 diabetes","volume":"656","author":"H\u00f6velmann","year":"2020"},{"key":"10.1016\/j.metabol.2021.154889_bb0280","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1056\/NEJMoa2022474","article-title":"Once-weekly insulin for type 2 diabetes without previous insulin treatment","volume":"383","author":"Rosenstock","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2021.154889_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc20-2878","article-title":"Randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100","volume":"44","author":"Lingvay","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.metabol.2021.154889_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dc20-2877","article-title":"Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial","volume":"44","author":"Bajaj","year":"2021","journal-title":"Diabetes Care"},{"issue":"suppl 1","key":"10.1016\/j.metabol.2021.154889_bb0295","article-title":"Preclinical development of an ultralong-acting insulin for once-weekly dosing. (Meeting abstract.)","volume":"66","author":"Howard","year":"2019","journal-title":"Diabetes"},{"issue":"suppl 1","key":"10.1016\/j.metabol.2021.154889_bb0300","article-title":"The in vitro and in vivo pharmacology of AB101, a potential once-weekly basal subcutaneous insulin. (Meeting abstract.)","volume":"64","author":"Roberts","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0305","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/dom.13006","article-title":"LAPSInsulin115: a novel ultra-long-acting basal insulin with a unique action profile","volume":"19","author":"Wronkowitz","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0310","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1146\/annurev.me.24.020173.001521","article-title":"Extraction of insulin by the liver","volume":"24","author":"Field","year":"1973","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.metabol.2021.154889_bb0315","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","article-title":"Control of glucose uptake and release by the liver in vivo","volume":"48","author":"Cherrington","year":"1999","journal-title":"Diabetes."},{"key":"10.1016\/j.metabol.2021.154889_bb0320","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/dom.12698","article-title":"Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3","volume":"18","author":"Bergenstal","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0325","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1136\/bmj.4.5785.447","article-title":"X rays and the structure of insulin","volume":"4","author":"Hodgkin","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.metabol.2021.154889_bb0330","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/nature11781","article-title":"How insulin engages its primary binding site on the insulin receptor","volume":"493","author":"Menting","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.metabol.2021.154889_bb0335","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd917","article-title":"Structural biology of insulin and IGF1 receptors: implications for drug design","volume":"1","author":"De Meyts","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.metabol.2021.154889_bb0340","series-title":"Endotext","article-title":"The insulin receptor and its signal transduction network","author":"De Meyts","year":"2016"},{"key":"10.1016\/j.metabol.2021.154889_bb0345","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj3150271","article-title":"Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency","volume":"315","author":"Hansen","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/j.metabol.2021.154889_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/diacare.39.1.1","article-title":"Insulin-mimetic effects of vanadate: possible implications for future treatment of diabetes","volume":"39","author":"Shechter","year":"1990","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2021.154889_bb0355","doi-asserted-by":"crossref","first-page":"15473","DOI":"10.1074\/jbc.M116.732180","article-title":"Insulin mimetic peptide disrupts the primary binding site of the insulin receptor","volume":"291","author":"Lawrence","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.metabol.2021.154889_bb0360","doi-asserted-by":"crossref","first-page":"101197","DOI":"10.1016\/j.isci.2020.101197","article-title":"Selection of small molecules that bind to and activate the insulin receptor from a DNA-encoded library of natural products","volume":"23","author":"Xie","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.metabol.2021.154889_bb0365","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/333679a0","article-title":"Monomeric insulins obtained by protein engineering and their medical implications","volume":"333","author":"Brange","year":"1988","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.metabol.2021.154889_bb0370","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/dom.13621","article-title":"BioChaperone lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: a randomized euglycemic clamp study","volume":"201","author":"Heise","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0375","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/dom.13685","article-title":"Better glycaemic control with BioChaperone glargine lispro co-formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes","volume":"21","author":"Meiffren","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2021.154889_bb0380","author":"Svehlikova"},{"key":"10.1016\/j.metabol.2021.154889_bb0385","series-title":"Ultra-fast and ultra-stable insulin formulations. ATTD presentation 2021; oral session 02","author":"Appel EA","year":"2021"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952100189X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002604952100189X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:29:01Z","timestamp":1758428941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002604952100189X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":77,"alternative-id":["S002604952100189X"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154889","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Future directions in insulin therapy","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2021.154889","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"154889"}}